Ainos (AIMD) Competitors $0.50 -0.04 (-8.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AIMD vs. PRLD, ADVM, ATNM, CNTX, VTVT, ANVS, AADI, APLT, RNXT, and PEPGShould you be buying Ainos stock or one of its competitors? The main competitors of Ainos include Prelude Therapeutics (PRLD), Adverum Biotechnologies (ADVM), Actinium Pharmaceuticals (ATNM), Context Therapeutics (CNTX), vTv Therapeutics (VTVT), Annovis Bio (ANVS), Aadi Bioscience (AADI), Applied Therapeutics (APLT), RenovoRx (RNXT), and PepGen (PEPG). These companies are all part of the "pharmaceutical products" industry. Ainos vs. Its Competitors Prelude Therapeutics Adverum Biotechnologies Actinium Pharmaceuticals Context Therapeutics vTv Therapeutics Annovis Bio Aadi Bioscience Applied Therapeutics RenovoRx PepGen Prelude Therapeutics (NASDAQ:PRLD) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to PRLD or AIMD? In the previous week, Prelude Therapeutics had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Ainos. Ainos' average media sentiment score of 1.89 beat Prelude Therapeutics' score of 1.83 indicating that Ainos is being referred to more favorably in the news media. Company Overall Sentiment Prelude Therapeutics Very Positive Ainos Very Positive Do analysts rate PRLD or AIMD? Prelude Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 316.67%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Prelude Therapeutics is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor PRLD or AIMD? Prelude Therapeutics received 33 more outperform votes than Ainos when rated by MarketBeat users. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes3351.56% Underperform Votes3148.44% AinosN/AN/A Which has higher earnings and valuation, PRLD or AIMD? Ainos has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M7.74-$121.83M-$1.69-0.57Ainos$106.21K98.53-$13.77M-$1.29-0.39 Is PRLD or AIMD more profitable? Prelude Therapeutics' return on equity of -66.89% beat Ainos' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% Ainos N/A -75.16%-50.22% Which has more risk & volatility, PRLD or AIMD? Prelude Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Ainos has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PRLD or AIMD? 79.7% of Prelude Therapeutics shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 10.4% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryPrelude Therapeutics beats Ainos on 9 of the 16 factors compared between the two stocks. Get Ainos News Delivered to You Automatically Sign up to receive the latest news and ratings for AIMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AIMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AIMD vs. The Competition Export to ExcelMetricAinosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.47M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.398.5527.1919.64Price / Sales98.53262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.106.536.974.60Net Income-$13.77M$143.48M$3.23B$248.06M7 Day Performance-23.53%0.20%-0.88%-1.02%1 Month Performance-6.67%10.93%7.81%3.51%1 Year Performance-38.55%2.46%31.53%12.68% Ainos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AIMDAinos1.3676 of 5 stars$0.50-8.0%N/A-35.5%$10.47M$106.21K-0.3940Positive NewsGap DownPRLDPrelude Therapeutics3.2404 of 5 stars$0.94+3.1%$4.00+327.7%-74.2%$52.81M$7M-0.53120Positive NewsGap DownADVMAdverum Biotechnologies3.9706 of 5 stars$2.51+3.3%$26.40+951.8%-67.1%$52.44M$1M-0.42190Positive NewsShort Interest ↑ATNMActinium Pharmaceuticals1.2005 of 5 stars$1.68+3.7%$4.00+138.1%N/A$52.41M$81K-1.2130CNTXContext Therapeutics3.0914 of 5 stars$0.58-1.0%$6.00+930.9%-67.4%$52.21MN/A-0.647Gap UpVTVTvTv Therapeutics1.6837 of 5 stars$16.30-1.5%$35.50+117.8%-24.8%$52.08M$17K-3.609Positive NewsANVSAnnovis Bio2.0834 of 5 stars$2.61-1.3%$34.75+1,233.5%-51.5%$50.78MN/A-0.583Analyst RevisionAADIAadi Bioscience0.6001 of 5 stars$1.74+3.0%$1.67-4.2%+17.6%$50.63M$25.07M-0.7640APLTApplied Therapeutics4.2653 of 5 stars$0.36+0.0%$6.10+1,613.5%-93.1%$50.40M$265K-0.2230Positive NewsRNXTRenovoRx2.9553 of 5 stars$1.37-3.5%$7.00+410.9%+16.2%$50.10M$240K-2.406Positive NewsShort Interest ↓High Trading VolumePEPGPepGen2.7389 of 5 stars$1.53+6.3%$7.67+401.1%-91.7%$50.06MN/A-0.5130Trending News Related Companies and Tools Related Companies PRLD Competitors ADVM Competitors ATNM Competitors CNTX Competitors VTVT Competitors ANVS Competitors AADI Competitors APLT Competitors RNXT Competitors PEPG Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AIMD) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ainos, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ainos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AIMD Stock Free AIMD Stock Alerts